Biotechnology research and developement

Die Kernkompetenz von TETEC liegt in der Entwicklung und Herstellung von neuartigen Zelltherapien.

The year 2000 marked the start of a new millennium – and with the founding of TETEC AG, the journey towards an innovative, cell-based therapy solution. With a passion for science and research and a drive to sustainably improve people’s health and quality of life, we specialise in tissue engineering technologies. This idea is reflected in our name: TETEC (TE = Tissue Engineering, TEC = Technology) stands for future-oriented treatment methods through autologous tissue replacement

Our core competence is in the area of promising biotechnology opportunities: the development and manufacture of novel cell therapies (ATMPs) and biomaterials for the treatment of complex human musculoskeletal damage and diseases – in particular cartilage damage. Our comprehensive research and development programme is also focussed on novel therapies for the treatment of conditions including osteoarthritis and chronic inflammatory diseases.

Cell therapies

Cell-based treatments and medicinal products for novel therapies

We develop and produce products for innovative treatments through our own projects as well as in cooperation with or on behalf of external partners. Our experts combine knowledge of cell and molecular biology with the highest level of clinical and pharmacological know-how – and set new standards in regenerative medicine in the process.

Different cell types and culture techniques, which may be combined with biomaterials specially developed for the respective therapy, are used for our products. To standardise manufacturing and quality assurance processes in each project, we develop our own procedures for the automated production of the products, their preliminary Steps, or individual components.

Cartilage reconstruction

Innovative products for the treatment of cartilage defects

TETEC entwickelt unterschiedliche Produkte zur biologischen Knorpelrekonstruktion.

Over the past 20 years, we have developed a range of products for innovative biological cartilage reconstruction procedures. The goal: to regenerate the damaged area of the joint surface with high-quality autologous cartilage tissue – and thus enable patients to live a pain-free and symptom-free life. Goal of therapy with our products: to enable the joint to withstand high loads over the long term and to ensure it is not subject to premature wear. The focus is also on surgery that is as minimally invasive and atraumatic as possible.

Smart biomaterials for cartilage regeneration and more

We have developed an injectable, in-situ crosslinking biomaterial with high compatibility and smart properties. Due to its physical properties, the hydrogel has a regenerative and cartilage-protecting effect. The biomaterial thus promotes cartilage regeneration and also anchors the implanted cartilage cells into the defect area.

In addition, the hydrogel ACIs as a modifiable platform technology in other therapeutic approaches: active pharmaceutical ingredients can be injected directly into the target tissue using the smart biomaterial and are released over a prolonged period of time. The oral intake of, for example, anti-inflammatory active substances in conventional osteoarthritis therapy can be replaced by local injections – and serious side effects could be significantly reduced as a result.


From clinic spin-off to innovative biotech company

In 2000, TETEC emerged as a spin-off biotechnological company from the Natural and Medical Sciences Institute (NMI) and the Berufsgenossenschaftliche Unfallklinik Tübingen. It later became part of the biologics business of Aesculap® Inc., whose parent company is the global B. Braun Group.

In 2024, TETEC was acquired by Octane Biotherapeutics, part of Octane Medical Group, a multinational medical technology company with the most advanced bioprocesses, biomaterials and bioreactors for regenerative medicine.

To date, we have manufactured more than 28,000 individual products under the NOVOCART® brand for the biological reconstruction of cartilage damage in different joints.

With more than 20 years of experience and expertise, TETEC AG is the European market leader in cartilage cell therapy, ATMPs (advanced therapy medicinal products) and suitable biomaterials.

Our location

Tomorrow’s research meets a down-to-earth attitude

Or location in Reutlingen serves as the ideal base for innovative developments and international sales. The region is characterised by a healthy, pragmatic down-to-earth attitude while, at the same time, lying in the heart of Europe: 25 minutes from Stuttgart Airport (STR) by car and a 2.5-hour drive away from Zurich.

Reutlingen and the surrounding region have a strong, forward-looking scientific and research tradition: TETEC AG is part of the BioRegio STERN biotech network, which currently includes 120 medtech companies and 110 biotech companies. Close collaborations with the local innovation hub NMI and the University of Tübingen are rooted in our origin story – and continue to exist today.

An international network of specialised service providers and research partnerships with biotechnology institutes, universities and industrial partners round off these structures. This allows us to guarantee you an excellent sales platform and support you with professional user training and support.

Our TETEC AG production facility with office building in Reutlingen 

Our mission

Tissue engineering for the health of the future

Our products are focussed on the matrix-associated autologous chondrocyte implantation (M-ACI) procedure. M-ACI been recommended by the German Society for Orthopaedics and Trauma Surgery (DGOU) as a standard treatment for cartilage defects since 2004. The 2022 recommendations refer to treatments of small defects up to 2 cm2 in size.[1] Our mission: With our products, we combine cell and molecular biology knowledge with clinical and pharmaceutical know-how at the highest level – for optimal, patient-specific care.  

CDMO services: Your partner for cell-based therapy solutions

But TETEC’s mission does not end with our products: with our CDMO services, we want to share our expertise, experience and know-how and grow at the same time. As your expert partner, we will support you in the development and manufacture of ATMPs – from idea through all the clinical phases all the way to the commercialisation of your finished product.

[1] https://pubmed.ncbi.nlm.nih.gov/35189656